<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40981239</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2226-4787</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Pharmacy (Basel, Switzerland)</Title><ISOAbbreviation>Pharmacy (Basel)</ISOAbbreviation></Journal><ArticleTitle>Evaluation of a Community Pharmacist-Led Intervention Program for Early Detection of Gastrointestinal Adverse Events of Dipeptidyl Peptidase-4 Inhibitors: A Multicenter, Non-Randomized Comparative Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmacy13050119</ELocationID><Abstract><AbstractText>In this multicenter, nonrandomised comparative study, we evaluated the potential effectiveness of a program to promote the safe use of dipeptidyl peptidase-4 (DPP-4) inhibitors led by community pharmacists. The program facilitated early detection of gastrointestinal adverse events (GIAEs) in patients newly prescribed DPP-4 inhibitors and facilitated timely communication with physicians. Community pharmacists reviewed patient conditions and provided relevant information to physicians as needed. GIAE monitoring based on the program was conducted in 35 patients at 10 pharmacies in Japan (intervention group) between March and August 2024. The proportion of pharmacist interventions was compared with that in 451 patients from March to August 2023, before program implementation (baseline cohort). The primary outcome, pharmacist intervention rate, was significantly higher in the intervention group (5 out of 35 patients, 14.3%) than in the baseline cohort (0 out of 451 patients, 0.0%) (<i>p</i> &lt; 0.001). GIAEs were identified in 13 out of 35 patients (37.1%) in the intervention group; information for five patients (14.3%) was shared with physicians, resulting in discontinuation of the DPP-4 inhibitor in one patient and addition of supportive therapy in others. Most GIAEs occurred within the first 1-2 weeks of therapy, highlighting the need for early intervention. Thus, proactive involvement of community pharmacists may improve the care process in these cases and contribute to healthcare coordination and diabetes care quality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Funabashi</LastName><ForeName>Ayana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AIN PHARMACIEZ INCORPORATED 1F, 2-7-1, Daigakumachi, Takatsuki 569-8686, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmacy, Department of Social and Administrative Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1, Nasahara, Takatsuki 569-1094, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>AIN HOLDINGS INCORPORATED JR South Shinjuku Building 11F, 2-1-5 Yoyogi, Shibuya, Tokyo 151-0053, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Mamoru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AIN HOLDINGS INCORPORATED JR South Shinjuku Building 11F, 2-1-5 Yoyogi, Shibuya, Tokyo 151-0053, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>AIN HOLDINGS INCORPORATED JR South Shinjuku Building 11F, 2-1-5 Yoyogi, Shibuya, Tokyo 151-0053, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukioka</LastName><ForeName>Ryota</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>AIN HOLDINGS INCORPORATED JR South Shinjuku Building 11F, 2-1-5 Yoyogi, Shibuya, Tokyo 151-0053, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onda</LastName><ForeName>Mitsuko</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5855-2727</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmacy, Department of Social and Administrative Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1, Nasahara, Takatsuki 569-1094, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmacy (Basel)</MedlineTA><NlmUniqueID>101678532</NlmUniqueID><ISSNLinking>2226-4787</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">community pharmacist</Keyword><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">dipeptidyl peptidase-4 inhibitors</Keyword><Keyword MajorTopicYN="N">follow-up care</Keyword><Keyword MajorTopicYN="N">gastrointestinal adverse events</Keyword><Keyword MajorTopicYN="N">tracing report</Keyword></KeywordList><CoiStatement>A.F. is an employee of AIN PHARMACIEZ INC. H.I., M.M., Y.H. and R.T. are employees of AIN HOLDINGS INC.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40981239</ArticleId><ArticleId IdType="pmc">PMC12452381</ArticleId><ArticleId IdType="doi">10.3390/pharmacy13050119</ArticleId><ArticleId IdType="pii">pharmacy13050119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deacon C.F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2020;16:642&#x2013;653. doi: 10.1038/s41574-020-0399-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-0399-8</ArticleId><ArticleId IdType="pubmed">32929230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.G., Hahn S., Oh T.J., Kwak S.H., Park K.S., Cho Y.M. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-analysis. Diabetologia. 2013;56:696&#x2013;708. doi: 10.1007/s00125-012-2827-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2827-3</ArticleId><ArticleId IdType="pubmed">23344728</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchi R., Sugiyama T., Goto A., Imai K., Ihana-Sugiyama N., Ohsugi M., Yamauchi T., Kadowaki T., Ueki K. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type&#x2009;2 diabetes in Japan. J. Diabetes Investig. 2022;13:280&#x2013;291. doi: 10.1111/jdi.13636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.13636</ArticleId><ArticleId IdType="pmc">PMC8847136</ArticleId><ArticleId IdType="pubmed">34309213</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131&#x2013;2157. doi: 10.1053/j.gastro.2007.03.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2007.03.054</ArticleId><ArticleId IdType="pubmed">17498508</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Hamdah R., Rabiee A., Meneilly G.S., Shannon R.P., Andersen D.K., Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab. 2009;94:1843&#x2013;1852. doi: 10.1210/jc.2008-1296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2008-1296</ArticleId><ArticleId IdType="pmc">PMC2690432</ArticleId><ArticleId IdType="pubmed">19336511</ArticleId></ArticleIdList></Reference><Reference><Citation>Marathe C.S., Rayner C.K., Jones K.L., Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp. Diabetes Res. 2011;2011:279530. doi: 10.1155/2011/279530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/279530</ArticleId><ArticleId IdType="pmc">PMC3124003</ArticleId><ArticleId IdType="pubmed">21747825</ArticleId></ArticleIdList></Reference><Reference><Citation>Banyu Pharmaceutical Co., Ltd  JANUVIA&#xae; Tablets Report on the Results of Post-Marketing Surveillance.  [(accessed on 21 May 2025)].  Available online:  https://www.msdconnect.jp/wp-content/uploads/sites/5/2021/02/eppv_midterm2_januvia_tab.pdf.</Citation></Reference><Reference><Citation>Kanasaki K., Konishi K., Hayashi R., Shiroeda H., Nomura T., Nakagawa A., Nagai T., Takeda-Watanabe A., Ito H., Tsuda S., et al. Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients. J. Diabetes Investig. 2013;4:673&#x2013;675. doi: 10.1111/jdi.12095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.12095</ArticleId><ArticleId IdType="pmc">PMC4020265</ArticleId><ArticleId IdType="pubmed">24843724</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammed A., Thomas C., Kalaiselvan V., Undela K. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: Findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials. Expert. Opin. Drug Saf. 2024;23:731&#x2013;742. doi: 10.1080/14740338.2023.2284992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2023.2284992</ArticleId><ArticleId IdType="pubmed">37986140</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto N. The Strategic Plan of the Japan Pharmaceutical Association. Yakugaku Zasshi. 2022;142:951&#x2013;963. doi: 10.1248/yakushi.22-00089-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/yakushi.22-00089-4</ArticleId><ArticleId IdType="pubmed">36047222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Labour and Welfare  Vision of Pharmacies for Patients.  [(accessed on 21 May 2025)].  Available online:  https://www.mhlw.go.jp/file/04-Houdouhappyou-11121000-Iyakushokuhinkyoku-Soumuka/vision_1.pdf.</Citation></Reference><Reference><Citation>Japan Pharmaceutical Association  Guidelines for Patients Follow-Up During Medication Use (Version 1.2)  [(accessed on 21 May 2025)].  Available online:  https://www.nichiyaku.or.jp/files/co/pharmacy-info/followup_1.2.pdf.</Citation></Reference><Reference><Citation>Fukuda Y., Suzuki M., Ito R., Inaba J., Kanemoto T., Sahara T., Tsujikawa M., Onda M. Utilization and issues related to discharge medication summaries from hospital pharmacies to community pharmacies. Yakugaku Zasshi. 2024;144:741&#x2013;748. doi: 10.1248/yakushi.23-00214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/yakushi.23-00214</ArticleId><ArticleId IdType="pubmed">38945848</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara N., Yamashita S., Seiki S., Tsutsui K., Kato-Hayashi H., Sakurai S., Niwa K., Kawai T., Kai J., Suzuki A., et al. Evaluation of steroid-induced osteoporosis prevention using tracing reports in collaboration between hospitals and community pharmacists. Pharmacy. 2024;12:80. doi: 10.3390/pharmacy12030080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmacy12030080</ArticleId><ArticleId IdType="pmc">PMC11130855</ArticleId><ArticleId IdType="pubmed">38804472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekiya S., Tanaka R., Iijima H., Nakano Y., Miyazaki S., Toyomi A., Hashiba H., Nagatsu M., Shikamura Y. A nationwide survey on medication follow-up care by community pharmacists: From the Japanese nationwide pharmacy collaboration survey in 2023. Yakugaku Zasshi. 2024;144:805&#x2013;813. doi: 10.1248/yakushi.24-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/yakushi.24-00016</ArticleId><ArticleId IdType="pubmed">39085057</ArticleId></ArticleIdList></Reference><Reference><Citation>Maehara M., Sugiyama M. A community pharmacist-led follow-up support in antipsychotics-induced adverse events. Int. J. Neuropsychopharmacol. 2025;28:i289&#x2013;i290. doi: 10.1093/ijnp/pyae059.512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyae059.512</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehuys E., Van Bortel L., De Bolle L., Van Tongelen I., Annemans L., Remon J.P., Giri M. Effectiveness of a community pharmacist intervention in diabetes care: A randomized controlled trial. J. Clin. Pharm. Ther. 2011;36:602&#x2013;613. doi: 10.1111/j.1365-2710.2010.01218.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2710.2010.01218.x</ArticleId><ArticleId IdType="pubmed">21143256</ArticleId></ArticleIdList></Reference><Reference><Citation>Halalau A., Sonmez M., Uddin A., Karabon P., Scherzer Z., Keeney S. Efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients, a randomized controlled trial&#x2014;&#x201c;Pharm-MD&#x201d;: Impact of clinical pharmacists in diabetes care. BMC Endocr. Disord. 2022;22:69. doi: 10.1186/s12902-022-00983-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12902-022-00983-y</ArticleId><ArticleId IdType="pmc">PMC8925057</ArticleId><ArticleId IdType="pubmed">35296307</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Assaf S., Zelko R., Hanko B. The Effect of Interventions Led by Community Pharmacists in Primary Care for Adults with Type 2 Diabetes Mellitus on Therapeutic Adherence and HbA1c Levels: A Systematic Review. Int. J. Environ. Res. Public Health. 2022;19:6188. doi: 10.3390/ijerph19106188.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19106188</ArticleId><ArticleId IdType="pmc">PMC9141685</ArticleId><ArticleId IdType="pubmed">35627724</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosli M.R., Neoh C.F., Wu D.B., Hassan N.W., Mahmud M., Rahimi A., Karuppannan M. Evaluation of home medication review for patients with type 2 diabetes mellitus by community pharmacists: A randomised controlled trial. Pharm. Pract. 2021;19:2397. doi: 10.18549/PharmPract.2021.3.2397.</Citation><ArticleIdList><ArticleId IdType="doi">10.18549/PharmPract.2021.3.2397</ArticleId><ArticleId IdType="pmc">PMC8455124</ArticleId><ArticleId IdType="pubmed">34621450</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint Commission of Pharmacy Practitioners  The Pharmacists&#x2019; Patient Care Process.  [(accessed on 3 August 2025)].  Available online:  https://jcpp.net/patient-care-process/</Citation></Reference><Reference><Citation>Mandelstam P., Lieber A. Esophageal dysfunction in diabetic neuropathy-gastroenteropathy. Clinical and roentgenological manifestations. JAMA. 1967;201:582&#x2013;586. doi: 10.1001/jama.1967.03130080024006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1967.03130080024006</ArticleId><ArticleId IdType="pubmed">5006759</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujishiro M., Kushiyama A., Yamazaki H., Kaneko S., Koketsu Y., Yamamotoya T., Kikuchi T., Sakoda H., Suzuki R., Kadowaki T. Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus. World J. Gastroenterol. 2017;23:6694&#x2013;6704. doi: 10.3748/wjg.v23.i36.6694.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i36.6694</ArticleId><ArticleId IdType="pmc">PMC5643290</ArticleId><ArticleId IdType="pubmed">29085214</ArticleId></ArticleIdList></Reference><Reference><Citation>Funabashi A., Ito H., Maeda M., Hasegawa Y., Tsukioka R., Onda M. Evaluation of dipeptidyl peptidase-4 inhibitor-associated gastrointestinal symptoms using the prescription claims database. Sci. Rep. 2025;15:11494. doi: 10.1038/s41598-025-96103-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-025-96103-6</ArticleId><ArticleId IdType="pmc">PMC11968886</ArticleId><ArticleId IdType="pubmed">40181088</ArticleId></ArticleIdList></Reference><Reference><Citation>Reghunath S.R., Chackochan A., Thunga G., Acharya D.U., Shivashankara K.N., Ravindra Prabhu A., Acharya L.D. Prevalence and Predictors of Adverse Events Associated With Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetic Patients: A Cross-sectional Study. Clin. Med. Insights Endocrinol. Diabetes. 2024;17:11795514241288645. doi: 10.1177/11795514241288645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11795514241288645</ArticleId><ArticleId IdType="pmc">PMC11526154</ArticleId><ArticleId IdType="pubmed">39483777</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman M.B., Tudrej B.V., Soustre J., Buisson M., Archambault P., Pouchain D., Vaillant-Roussel H., Gueyffier F., Faillie J.L., Perault-Pochat M.C., et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017;43:48&#x2013;58. doi: 10.1016/j.diabet.2016.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2016.09.005</ArticleId><ArticleId IdType="pubmed">27745828</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai T., Wada Y., Kokan A., Tanabe K., Goto N., Ohtsu F. Creating a checklist and a survey on research that used the Japanese Adverse Drug Event Report database. Jpn. J. Drug Inf. 2020;22:7&#x2013;16.</Citation></Reference><Reference><Citation>Nomura K., Takahashi K., Hinomura Y., Kawaguchi G., Matsushita Y., Marui H., Anzai T., Hashiguchi M., Mochizuki M. Effect of database profile variation on drug safety assessment: An analysis of spontaneous adverse event reports of Japanese cases. Drug Des. Dev. Ther. 2015;9:3031&#x2013;3041. doi: 10.2147/DDDT.S81998.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S81998</ArticleId><ArticleId IdType="pmc">PMC4472069</ArticleId><ArticleId IdType="pubmed">26109846</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkhout C., Berbra O., Favre J., Collins C., Calafiore M., Peremans L., Van Royen P. Defining and evaluating the Hawthorne effect in primary care, a systematic review and meta-analysis. Front. Med. 2022;9:1033486. doi: 10.3389/fmed.2022.1033486.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1033486</ArticleId><ArticleId IdType="pmc">PMC9679018</ArticleId><ArticleId IdType="pubmed">36425097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>